Cancel
Michail Shipitsin
Biomarker Development
@
Acrivon Therapeutics
4w872d6f66@j5eluzl.ug3
Sign up to see email
See Linkedin
Known information
- Over 15 years of expertise in translational and clinical biomarker research and development.
- Pioneer of automated, digital multiplex imaging and clinical biomarker tests.
- Previously, Director and Head of Biomarker Development at Metamark Genetics and XTuit Pharmaceuticals.
- Completed postdoctoral studies at Dana-Farber Cancer Institute with a focus on biomarkers in breast cancer.
- Scientific lead on the first-of-a-kind marketed, automated quantitative prognostic prostate cancer test, ProMark®.
- Earned a Diploma in Molecular Biology from Novosibirsk State University.
- Completed a Ph.D. in Biochemistry from Tufts University.
About Acrivon Therapeutics
Acrivon Therapeutics develops precision oncology medicines using a proprietary proteomics-based platform, with its lead candidate ACR-368 in a Phase 2 trial for multiple tumor types.
Report inaccurate information
